PURPOSE: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. EXPERIMENTAL DESIGN: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. RESULTS: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. CONCLUSIONS: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.
PURPOSE: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. EXPERIMENTAL DESIGN: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. RESULTS: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. CONCLUSIONS: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.
Authors: Gregory R Bean; Catherine Ibarra Drendall; Vanessa K Goldenberg; Joseph C Baker; Michelle M Troch; Carolyn Paisie; Lee G Wilke; Lisa Yee; Paul K Marcom; Bruce F Kimler; Carol J Fabian; Carola M Zalles; Gloria Broadwater; Victoria Scott; Victoria L Seewaldt Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-01 Impact factor: 4.254
Authors: Charles R Holst; Gerard J Nuovo; Manel Esteller; Karen Chew; Stephen B Baylin; James G Herman; Thea D Tlsty Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Carol J Fabian; Bruce F Kimler; Deborah A Brady; Matthew S Mayo; C H Joseph Chang; John A Ferraro; Carola M Zalles; Annette L Stanton; Shahla Masood; William E Grizzle; Norman F Boyd; Dora W Arneson; Karen A Johnson Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Martin Widschwendter; Kimberly D Siegmund; Hannes M Müller; Heidi Fiegl; Christian Marth; Elisabeth Müller-Holzner; Peter A Jones; Peter W Laird Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Sangjun Lee; Syed K Mohsin; Sufeng Mao; Susan G Hilsenbeck; Dan Medina; D Craig Allred Journal: Breast Cancer Res Date: 2005-12-16 Impact factor: 6.466
Authors: David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis Journal: Cancer Prev Res (Phila) Date: 2011-07-21
Authors: Catherine Ibarra-Drendall; Lee G Wilke; Carola Zalles; Victoria Scott; Laura E Archer; Siya Lem; Lisa D Yee; Joanne Lester; Swati Kulkarni; Christine Murekeyisoni; Marie Wood; Karen Wilson; Judy Garber; Carleen Gentry; April Stouder; Gloria Broadwater; Joseph C Baker; Shauna N Vasilatos; Elizabeth Owens; Sarah Rabiner; Abbey C Barron; Victoria L Seewaldt Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-04-21 Impact factor: 4.254
Authors: Shauna N Vasilatos; Gloria Broadwater; William T Barry; Joseph C Baker; Siya Lem; Eric C Dietze; Gregory R Bean; Andrew D Bryson; Patrick G Pilie; Vanessa Goldenberg; David Skaar; Carolyn Paisie; Alejandro Torres-Hernandez; Tracey L Grant; Lee G Wilke; Catherine Ibarra-Drendall; Julie H Ostrander; Nicholas C D'Amato; Carola Zalles; Randy Jirtle; Valerie M Weaver; Victoria L Seewaldt Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-03 Impact factor: 4.254
Authors: William H Goodson; Maria Gloria Luciani; S Aejaz Sayeed; Ian M Jaffee; Dan H Moore; Shanaz H Dairkee Journal: Carcinogenesis Date: 2011-09-01 Impact factor: 4.944
Authors: Brian J Girard; Tarah M Regan Anderson; Siya Lem Welch; Julie Nicely; Victoria L Seewaldt; Julie H Ostrander Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240